Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 May 1;73(9):924-30.
doi: 10.1016/j.biopsych.2012.09.025. Epub 2012 Nov 22.

Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial

Andrea C King  1 , Dingcai Cao, Lingjiao Zhang, Stephanie S O'Malley
Affiliations
Randomized Controlled Trial

Naltrexone reduction of long-term smoking cessation weight gain in women but not men: a randomized controlled trial

Andrea C King et al. Biol Psychiatry. .

Abstract

Background: The opioid antagonist naltrexone has shown promise to reduce weight gain during active treatment, but longer-term studies have not been conducted. The goal was to examine effects of naltrexone on weight gain over long-term follow-up in men and women who quit smoking.

Methods: Weight was examined at baseline and 6- and 12-month follow-up in the two largest randomized, double-blind, placebo-controlled trials of naltrexone in nicotine dependence. For 6-12 weeks after the quit date, participants were randomly assigned to receive naltrexone or placebo. Behavioral counseling and open-label nicotine patch were also included for the first 4-6 weeks. Of the 700 participants in the combined intent-to-treat sample, there were 159 (77 women) biochemically verified abstinent smokers at 6 months, and 115 (57 women) of them remained abstinent at 12 months. Changes in weight (in kilograms or in percentage) and body mass index from baseline to the follow-ups were assessed for these participants.

Results: Weight gain was significantly lower for women treated with naltrexone compared with placebo (6 months, 3.3 vs. 5.5 kg; 12 months, 5.9 vs. 7.4 kg, respectively). Increases in body mass index and percentage body weight gain were also significantly lower in women treated with naltrexone versus placebo. These effects were not observed in men.

Conclusion: The results provide evidence for naltrexone as the first pharmacotherapy to reduce postsmoking cessation weight gain among women.

Trial registration: ClinicalTrials.gov NCT00218153 NCT00271024.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Weight change in 6- and 12-month smoking abstainers. *p < .05.
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention (CDC) NCfHSN J. National Health and Nutrition Examination Survey Data. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2011.
    1. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238–1245. - PubMed
    1. US Department of Health and Human Services JL. Health People 2000. Washington, DC: US Government Printing Office; 1990.
    1. Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2012;1:CD006219. - PubMed
    1. Williamson DF, Madans J, Anda RF, Kleinman JC, Giovino GA, Byers T. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med. 1991;324:739–745. - PubMed

Publication types

Associated data